Paragon 28 Reveals CFO Transition

Paragon 28 announced that chief financial officer (CFO) Stephen Deitsch is departing the company to pursue an opportunity with OrganOx, a UK-based company focused on therapeutic applications of isolated organ perfusion. Deitsch will leave the company on April 5, 2024.
 
The company revealed the appointment of Kristina Wright as its interim CFO, effective April 3. Wright has been a member of Paragon 28’s board of directors since 2021 and is currently chair of the company’s audit committee, as well as a member of the nominating and corporate governance committee.
 
Upon assuming the CFO role, Wright stepped down temporarily from her roles as chair of the audit committee and member of the nominating and corporate governance committee. Thomas Schnettler, Paragon 28’s lead independent director, will assume the position of interim chair of the audit committee.
 
“I would like to thank Steve for his many contributions to our organization, including his leadership during the company’s initial public offering,” said Paragon 28 CEO Albert DaCosta. “He has been a trusted partner since joining the company in 2020, helping to steer our strong growth through a transformative time for Paragon 28. Further, Steve has been instrumental in building our operational capabilities and fortifying our balance sheet to position the Company for sustainable long-term growth. We wish him continued success with his new venture. We are also very fortunate to have Krissy in our organization. She is an experienced financial executive whose knowledge of the company will enable her to successfully lead our finance team through this interim period.”
 
Deitsch said, “It has been a privilege to be part of Paragon 28 and to work with such a passionate team to advance our mission to improve foot and ankle outcomes. I want to thank Albert, the Board of Directors and the leadership team for my time at Paragon 28. I am incredibly proud of our accomplishments over the past several years to scale the business and I look forward to seeing the company continue its remarkable mission.”
 
Earlier this week, the company launched its new Grappler R3INFORCE extraosseous repair system, which restores stability to anterior and posterior ligaments surrounding the ankle during fibular fracture repairs and high ankle sprains.